The Evolution of Radioligand Therapy: Next-Generation Strategies to Expand the Therapeutic Window
The design and application of radioactively labeled drugs for cancer treatment are experiencing a rebirth, led in part by new advances in radioligand therapies (RLTs) like 177 Lu-PSMA-617 and 177 Lu-DOTATATE that specifically and potently bind to proteins highly upregulated in cancer. This review discusses the latest advances in RLT design that aim to maximize radiation delivery to tumor tissue while sparing normal tissues from greater than minimal radioactive dose.
Authors
- Apurva Pandey (ORCID: https://orcid.org/0000-0001-6944-2518)
- Michael J. Evans (ORCID: https://orcid.org/0000-0003-4947-1316)
- Luke N. Jaskowski
Institutions
- University of California, San Francisco (US)
- University of California System (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- Annual Review of Cancer Biology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1146/annurev-cancerbio-070524-031441
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00